Search

Your selection

None

Filter by content type

Filter by content year

News

Vaxart to Present Norovirus Data at IDWeek 2024 Underscoring Commitment to Address Significant Unmet Need

October 15, 2024 - … $10.6 billion Presentation Information: Title: A Phase 2 Double-Blind, Placebo-Controlled Study Showing Oral Tableted … PT Room: 404 AB Title: A Phase I, Multicenter, Randomized, Double-blind, Placebo-controlled Single Dose, Dose-ranging … $10.6 billion Presentation Information: Title: A Phase 2 Double-Blind, Placebo-Controlled Study Showing Oral Tableted …
News

Results from Influenza Challenge Study Published in Lancet Infectious Diseases

January 22, 2020 - … The Phase 2 influenza A challenge trial was a randomized, double-blind study consisting of three groups. Subjects … injection, a QIV injection and a placebo tablet, or a double placebo. Subjects were challenged intranasally with … The Phase 2 influenza A challenge trial was a randomized, double-blind study consisting of three groups. Subjects …
News

Vaxart Announces Publication of Complete Data from Preclinical COVID-19 Oral Vaccine Hamster Challenge Study in Journal of Infectious Diseases

November 16, 2021 - … measure of lung inflammation, was significantly lower in double-vaccinated hamsters compared with unvaccinated animals. Five days post challenge, double-vaccinated hamsters had a greater than 4 log reduction … measure of lung inflammation, was significantly lower in double-vaccinated hamsters compared with unvaccinated …
News

Vaxart Publishes Positive Data for its Oral Bivalent Norovirus Candidate in Lactating Women and Their Infants

January 15, 2026 - … announced the publication in npj Vaccines of data from a double-blind, placebo-controlled Phase 1 trial evaluating a … About the Trial The Phase 1, multicenter, randomized, double-blind, placebo-controlled single dose, dose-ranging … announced the publication in npj Vaccines of data from a double-blind, placebo-controlled Phase 1 trial evaluating a …
News

Vaxart Completes Dosing of the Lead-In Cohort in Bivalent Norovirus Vaccine Phase 1b Clinical Trial

March 27, 2019 - … phase which has now been completed, and a randomized, double-blind, placebo-controlled phase which is expected to … phase which has now been completed, and a randomized, double-blind, placebo-controlled phase which is expected to … phase which has now been completed, and a randomized, double-blind, placebo-controlled phase which is expected to …
News

Vaxart Doses First Patient in Randomized Cohort of Bivalent Norovirus Vaccine Phase 1b Clinical Trial

April 16, 2019 - … successfully earlier this month, and a randomized, double-blind, placebo-controlled phase which has now started. … successfully earlier this month, and a randomized, double-blind, placebo-controlled phase which has now started. … successfully earlier this month, and a randomized, double-blind, placebo-controlled phase which has now started. …
News

Vaxart Announces Initiation of Bivalent Norovirus Vaccine Phase 1b Clinical Trial

March 19, 2019 - … subjects will be dosed with norovirus GII.4 vaccine, and a double-blind, placebo-controlled phase during which a total … subjects will be dosed with norovirus GII.4 vaccine, and a double-blind, placebo-controlled phase during which a total … subjects will be dosed with norovirus GII.4 vaccine, and a double-blind, placebo-controlled phase during which a total …
News

Vaxart Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial

May 15, 2025 - … our clinical development program.” The Phase 2b trial is a double-blind, multi-center, randomized, comparator-controlled … our clinical development program.” The Phase 2b trial is a double-blind, multi-center, randomized, comparator-controlled … our clinical development program.” The Phase 2b trial is a double-blind, multi-center, randomized, comparator-controlled …
News

New Data from Phase 2 Flu Challenge Study Demonstrates Vaxart’s Oral H1 Flu Vaccine Generated Protective Mucosal Immunity

News

Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial

January 13, 2025 - … at least 25% over the age of 65. The Phase 2b trial is a double-blind, multi-center, randomized, comparator-controlled … at least 25% over the age of 65. The Phase 2b trial is a double-blind, multi-center, randomized, comparator-controlled … at least 25% over the age of 65. The Phase 2b trial is a double-blind, multi-center, randomized, comparator-controlled …
Scroll to Top